Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D

Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D

Source: 
Xconomy
snippet: 

Stoke Therapeutics is the latest biotech company to debut on Wall Street, raising $142 million to test an experimental therapy for a rare form of epilepsy.